Truist raised the firm’s price target on AdaptHealth (AHCO) to $13 from $11 and keeps a Buy rating on the shares. The company’s Q4 revenue and adjusted EBITDA were well ahead of estimates, driven by ongoing strength in Sleep/Respiratory, strong cost management and improvement in the Humana (HUM) contract implementation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AHCO: